EIM
ALDX icon

Essex Investment Management’s Aldeyra Therapeutics ALDX Stock Holding History

Essex Investment Management’s Portfolio ALDX Stock Details ALDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-39,215
Closed -$312K – 400
2018
Q2 		$312K Buy
+39,215
New +$313K 0.04% 334

Other funds holding ALDX

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return

Essex Investment Management's ALDX Position: Q3 2018 in Review

Essex Investment Management sold out of Aldeyra Therapeutics (ALDX) in Q3 2018, closing a stake of 39,215 shares — an estimated $312K sold.

Essex Investment Management first reported a position in ALDX in Q2 2018 and held it in 1 quarter. The position peaked at $312K in Q2 2018. 89 funds tracked by Wall St. Rank hold ALDX as of Q3 2018.

  • Essex Investment Management reported no remaining Aldeyra Therapeutics position as of Q3 2018 after selling out during the quarter.
  • Essex Investment Management sold 39,215 Aldeyra Therapeutics shares in Q3 2018, an estimated $312K.
  • Essex Investment Management first reported a position in Aldeyra Therapeutics in Q2 2018 and held it in 1 quarter.
  • Essex Investment Management's Aldeyra Therapeutics position peaked at $312K in Q2 2018.
  • 89 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q3 2018.

Based on Essex Investment Management's 13F filing for Q3 2018, filed 16 Oct 2018.